Furthermore, we show using intravital (in vivo) imaging that NID2 reduction in CAFs causes reduced tumor fibrosis and vascular changes as well as an enhanced response to gemcitabine/Abraxane [nanoparticle albumin–bound paclitaxel (nab-paclitaxel)] chemotherapy. This evidence concerns the gene NID2 and neoplasm.